CURRICULUM VITAE ET STUDIORUM
DELLA DOTT.SSA Florence Michèle MALISAN
DATI ANAGRAFICI
Nome Florence Michèle MALISAN
Data e luogo di nascita 15/06/1969, Albertville (Francia)
Cittadinanza Francese e Italiana
Stato civile coniugata VISCO, 3 figli
Indirizzo Via Montpellier 1 – 00133 Rome
+39 06 72596504
Malisan@med.uniroma2.it
Lingue conosciute Francese, Inglese e Italiano
POSIZIONE
2017 - oggi Professore Associato (MEDS-26/A), Dipartimento di Biomedicina e Prevenzione, Università di Roma "Tor Vergata”
2006 - 2017 Ricercatore MED/04, Dipartimento di Biomedicina e Prevenzione,
Università di Roma "Tor Vergata”
TITOLI DI STUDIO
- 1996: PhD in Immunologia, con votazione “Molto onorevole con lodi” concessa all’unanimità e riservata al 10% delle migliori tesi dell’Université Claude Bernard, Lyon I, France.
- 1992: Laurea in Biologia: Master 2 di “Différenciation, Génétique et Immunologie”, Università Claude Bernard di Lyon, France.
- 1987: Maturità scientifica (Baccalauréat série D) at Annecy, France.
PREMI E RICONOSCIMENTI
- 1996-1998: Borsa post-dottorato Europea (EEC) Human Mobility Capital
- 1999-2001: Borsa post-dottorato Fondazione Italiana per la Ricerca sul Cancro (FIRC).
TRAINING
- 1992-1996: PhD, Schering-Plough, France, sotto la direzione dei Dott. J. Banchereau and H. Martinez-Valdez: "Cellular and molecular biology on human B cells".
- 1993-1994: Visiting PhD student at Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, MD, USA, under the direction of Drs E.E. Max e F.C. Mills:
- 1998: Visiting researcher at Department of Molecular Toxicology, Faculty of Biology, University of Konstanz, Germany, sotto la direzione del Prof. P. Nicotera,.
- 2002-2005: Research Associate: Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata”.
BREVETTI
Methods of treating Friedreich’s ataxia using Src inhibitors, assigned serial no. PCT/IB2015/059963, published 30 June 2016, n. WO2016103223 A1.
FINANZIAMENTI
- PRIN 2022 PNRR-M4C2 I.1.1 “Fondo per il Programma Nazionale di Ricerca e PRIN”, codice identificativo MUR ” P2022LZXNW_001, ”Simultaneous inhibition of multiple signaling transduction pathways by drugs combination in poor prognosis tumors”, Collaborator.
-Telethon-AFM: Involvement of protein kinase CK2 in the Friedreich’s ataxia, Grant 22974, 12 months, Team leader.
-AFAF: Association Française Ataxie de Friedreich, Study of the physiological variations of microRNAs in Friedreich’s ataxia to examine which of them may be important as new biomarkers for cardiomyopathy, 12 months, Co-investigator.
-University Mission Sustainability (2018): HAX-1 splice variants as potential molecular biomarkers for cardiomyopathies.Principal Investigator.
-National Ataxia Foundation (2018): HAX-1 is a biomarker for cardiomyopathies in Friedreich’s Ataxia. Principal Investigator.
ATTIVITÀ DI RICERCA
L'esperienza della Prof.ssa Florence Malisan (IF: 251, 40 articoli peer-reviewed, H-index-24, Citazioni >2100, ORCID ID 0000-0002-0213-9407) in biologia molecolare e biochimica comprende un'ampia gamma di discipline, tra cui biologia molecolare, biologia cellulare, biologia dei glicolipidi, trasfezione cellulare, espressione genica, proteomica, analisi proteica e rilevamento tramite western blot, citometria a flusso, immunofluorescenza, ELISA.
Negli ultimi 15 anni ha studiato il ruolo della frataxina, la proteina carente nel disordine genetico denominato Atassia di Friedreich (FRDA). Sia la patofisiologia molecolare che nuovi approcci terapeutici sono oggetto di indagine (http://www.labst.org). Recentemente, la sua ricerca si è concentrata sull'identificazione di potenziali biomarcatori diagnostici e prognostici specifici per la FRDA. Ha riportato che la deficienza di frataxina nella FRDA è effettivamente associata a livelli ridotti della proteina antiapoptotica HAX-1, un regolatore della morte e della sopravvivenza dei cardiomiociti. Ha inoltre dimostrato una significativa modulazione dell'espressione di HAX-1 mediante i livelli di frataxina nei cardiomiociti umani AC16, suggerendo quindi HAX-1 come potenziale biomarcatore di malattia cardiaca nella FRDA. Poiché HAX-1 - proteina cruciale per la sopravvivenza dei neuroni e dei cardiomiociti - è un biomarcatore potenziale della progressione della malattia, ha attivato una collaborazione con la Dr.ssa Francesca Amati e la Dr.ssa Caterina Mariotti per analizzare i microRNA circolanti correlati a HAX-1 poiché rappresentano interessanti biomarcatori non invasivi che potrebbero aiutare la pratica clinica.
PUBBLICAZIONI
ORCID ID 0000-0002-0213-9407
https://pubmed.ncbi.nlm.nih.gov/?term=malisan+f&sort=date
https://www.scopus.com/results/authorNamesList.uri?name=name&st1=malisan&st2=florence&origin=searchauthorlookup
DIDATTICA
Insegna Immunologia nei Corsi di Laurea in Medicina e Chirurgia (dal 2006), in Medicine and Surgery (dal 2013), Pharmacy (dal 2009), Tecniche di Laboratorio Biomedico (2018-2023) e Dietistica (dal 2018) dell'Università degli Studi di Roma Tor Vergata.
I
CURRICULUM VITAE
Name Florence Michèle MALISAN
Birthdate 15/06/1969, Albertville (France)
Nationality French and Italian
Status Married VISCO, 3 children
Address Via Montpellier 1 – 00133 Rome
+39 06 72596504
Malisan@med.uniroma2.it
Languages French: native proficiency
Italian: bilingual proficiency
English: full professional proficiency
Actual Position
2017 - date Associate Professor (MEDS-26/A), Department of Biomedicine
and Prevention, University of Rome Tor Vergata
2006 - 2017 Researcher - Assistant Professor (MED/04), Department of Biomedicine
and Prevention, University of Rome Tor Vergata
Education
- 1996: PhD in Immunology, with highest Honour -awarded to 10% of the best theses- at the University Claude Bernard of Lyon, in France.
- 1992: Degree in Biological Sciences (Master 2) at the University Claude Bernard of Lyon, in France.
- 1987: High School Diploma in Sciences at Annecy, France.
Awarded fellowships
- 1996-1998: EEC Human Mobility Capital postdoctoral fellowship
- 1999-2001: Postdoctoral Research fellowship from Italian Foundation for Cancer Research (FIRC).
Research experience
- 1992-1996 : PhD, Schering-Plough, France, under the direction of Drs J. Banchereau and H. Martinez-Valdez: "Cellular and molecular biology on human B cells".
- 1993-1994: Visiting PhD student at Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, MD, USA, under the direction of Drs E.E. Max e F.C. Mills.
- 1998: Visiting researcher at Department of Molecular Toxicology, Faculty of Biology, University of Konstanz, Germany, under the direction of Prof. P. Nicotera.
- 2002-2005: Research Associate: Department of Experimental Medicine and Biochemical Sciences, University of Rome "Tor Vergata”.
Research activity
The expertise of Prof. Florence Malisan (IF: 251, 40 peer-reviewed papers, H-index-24, Citations >2100, ORCID ID 0000-0002-0213-9407) in molecular and biochemical biology encompasses a wide range of areas including molecular biology, cell biology, glycolipid biology, cell transfection, in vitro gene delivery, gene expression, proteomics, protein analysis and detection by western blot, flow cytometry, immunofluorescence, ELISA.
During the last 15 years she studied the role of the frataxin protein in the genetic disease Friedreich’s ataxia (FRDA). Both molecular pathophysiology and novel therapeutic approaches are under investigation (http://www.labst.org).
Recently, her research focused on the identification of potential diagnostic and prognostic specific biomarkers of FRDA. She reported that frataxin deficiency in FRDA is indeed associated with reduced levels of antiapoptotic proteinHAX-1, a regulator of cardiomyocyte death and survival. She also demonstrated a significant modulation of HAX-1 expression by frataxin levels in AC16 human cardiomyocytes, thus suggesting HAX-1 as a potential biomarker of cardiac disease in FRDA. Since HAX-1 - crucial protein for neurons and cardiomyocytes survival - is a putative biomarker of disease progression, she activated a strong collaboration with Dr. Francesca Amati and Dr. Caterina Mariotti in order to analyse HAX-1 related circulating microRNAs as they represent interesting non-invasive biomarkers that could help clinical practice.
Patents
Methods of treating Friedreich’s ataxia using Src inhibitors, assigned serial no. PCT/IB2015/059963, published 30 June 2016, n. WO2016103223 A1.
Grants
- PRIN 2022 PNRR-M4C2 I.1.1 “Fondo per il Programma Nazionale di Ricerca e PRIN”, codice identificativo MUR ” P2022LZXNW_001, ”Simultaneous inhibition of multiple signaling transduction pathways by drugs combination in poor prognosis tumors”, Collaborator.
-Telethon-AFM (2020): Involvement of protein kinase CK2 in the Friedreich’s ataxia, Grant 22974, 12 months, Team leader.
-AFAF (2020): Association Française Ataxie de Friedreich, Study of the physiological variations of microRNAs in Friedreich’s ataxia as new biomarkers for cardiomyopathy, 12 months, Co-investigator.
-University Mission Sustainability (2018): HAX-1 splice variants as potential molecular biomarkers for cardiomyopathies. Principal Investigator.
-National Ataxia Foundation (2018): HAX-1 is a biomarker for cardiomyopathies in Friedreich’s Ataxia. Principal Investigator.
Teaching
She is in charge of Immunology courses in Degree course in Medicine and Surgery (since 2006 in Italian and 2013 in English), Pharmacy (since 2009), Biomedical Laboratory Techniques (2018 - 2023) and Dietetics (since 2018).
Publications
ORCID ID 0000-0002-0213-9407
https://pubmed.ncbi.nlm.nih.gov/?term=malisan+f&sort=date
https://www.scopus.com/results/authorNamesList.uri?name=name&st1=malisan&st2=florence&origin=searchauthorlookup
nsert here the curriculum